Study results indicate that mutation strength may shape both tumor–immune system interactions and immunotherapy response.
Abstract: Non-small cell lung cancer (NSCLC) remains the major contributor to global deaths annually. A slow and long screening and diagnostic process may lower 5-year survival rates. In cancer ...
Researchers at LUMC have made a breakthrough in understanding PALB2 mutations, an important cause of hereditary breast cancer ...
The SCN2A Foundation today announced a research collaboration with Unravel Biosciences, Inc., an AI-enabled therapeutics ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results